InSyBio reveals novel diagnostic and prognostic biosignature for Glioblastoma and announces its presentation at the 11th annual RECOMB/ISCB Conference on Regulatory & Systems Genomics

InSyBio’s R&D team applying the company’s proprietary predictive biomarker technology to a collection of data from open omics repositories came up with a novel biosignature of 13 transcripts and a predictive model for glioblastoma diagnosis and treatment. The biosignature not only increases significantly the diagnostic accuracy for glioblastoma but it is able to differentiate it from other types of brain tumors. Additional validation experiments are planned by InSyBio team, as this biosignature, combined with the trained machine learning models can become a strong tool in the hands of physicians not only for diagnostic-screening purposes but also for personalizing glioblastoma treatment by classifying patients into meaningful genomic phenotypes.

This work entitled as “Combining Network Theory and Machine Learning to Identify a Diagnostic and Prognostic Biosignature for Glioblastoma” was accepted for a poster presentation (poster #54) at the 11th Annual RECOMB/ISCB Conference on Regulatory & Systems Genomics, 10-12 December 2018, New York. It will be presented on the Poster Session 5:30 pm – 7:00 pm on Monday 10th of December 2018.

Mackenzie Hastings, the neuroscientist of InSyBio, business development associate and the company’s representative in the conference stated: “Glioblastoma is the most aggressive and lethal form of brain cancer but with InSyBio’s novel approach of biological network comparison, we were able to take an unparalleled leap in the pursuit of better diagnosis and treatment through our discovery of a novel, 13-transcript biomarker signature capable of diagnosing both tumor subtype and genetic profile with higher predictive accuracy than any other state-of-the-art method”. Mackenzie will be present in all three days of the conference and everyone interested in arranging an one-to-one meeting with her in the context of the conference should contact her before the conference via email at .

InSyBio’s CEO, Labros Digonis, stated that: “InSyBio has been enrolled for the fight against cancer and specifically against aggressive, currently untreated forms of Cancer such as Glioblastoma. RECOMB/ISCB is considered among the top international conferences for computational and systems biology research and we consider it as a perfect match for us to present our research. Though our participation in this conference we are seeking for collaborators which can contribute to validating and interpreting the glioblastoma biosignature we have uncovered as well as molecular biologists who can benefit from the utilization of our biomarker discovery technology”.

About the conference: The RECOMB/ISCB Conference on Regulatory and Systems Genomics with DREAM Challenges ( is one of the premier annual meetings in the fields of regulatory genomics, systems biology, and network visualization. This multidisciplinary conference brings together both computational and experimental researchers from across the world to discuss recent discoveries about genomic and molecular regulatory networks as well as innovative, integrative methods for developing a systems-level understanding of biological activity.

About InSyBio: InSyBio is an international bioinformatics pioneer company in precision medicine and nutrition, which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research goals (such as robust biomarker discovery and accurate predictive models). Since 2013, InSyBio has worked with hundreds of academics, companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an average increase of 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

InSyBio participates in the NBG Business Seeds and the International Accelerator Programs.

For any further detail contact our Business Development Manager, Mackenzie Hastings, at .

For more News visit our InSyBio Blog.

Scroll to top